UroGen Pharma (URGN) Misses Q4 EPS by 6c

UroGen Pharma (NASDAQ: URGN) reported Q4 EPS of ($0.54), $0.06 worse than the analyst estimate of ($0.48). Revenue for the quarter came in at $37.84 million versus the consensus estimate of $41.45 million.

For earnings history and earnings-related data on UroGen Pharma (URGN) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Gamma Resources raises private placement ceiling to $1.75M
• Zentek shares to move from Nasdaq to OTC Markets on Sept. 2